Literature DB >> 25457432

Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?

Sylvain Lehmann1, Audrey Gabelle2, Claire Paquet3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25457432     DOI: 10.1016/j.jalz.2014.09.003

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  5 in total

1.  Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.

Authors:  Hanne Struyfs; Ellis Niemantsverdriet; Joery Goossens; Erik Fransen; Jean-Jacques Martin; Peter P De Deyn; Sebastiaan Engelborghs
Journal:  Front Neurol       Date:  2015-06-17       Impact factor: 4.003

2.  Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios.

Authors:  Cecilia Marelli; Laure-Anne Gutierrez; Nicolas Menjot de Champfleur; Celine Charroud; Delphine De Verbizier; Jacques Touchon; Patrice Douillet; Claudine Berr; Sylvain Lehmann; Audrey Gabelle
Journal:  Alzheimers Dement (Amst)       Date:  2015-06-28

Review 3.  Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.

Authors:  Xi-Lin Wu; Juan Piña-Crespo; Yun-Wu Zhang; Xiao-Chun Chen; Hua-Xi Xu
Journal:  Chin Med J (Engl)       Date:  2017-12-20       Impact factor: 2.628

4.  Network-constrained technique to characterize pathology progression rate in Alzheimer's disease.

Authors:  Fon Powell; Duygu Tosun; Ashish Raj
Journal:  Brain Commun       Date:  2021-07-15

5.  CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment.

Authors:  Azadeh Karami; Taher Darreh-Shori; Marianne Schultzberg; Maria Eriksdotter
Journal:  Front Aging Neurosci       Date:  2021-08-26       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.